A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs PL MLP (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lipomedix Pharmaceuticals
- 04 Jul 2017 Number of arms changed from 10 to 12,hence patient number has also changd from 48 to 90.
- 04 Jul 2017 Planned number of patients changed from 48 to 90.
- 04 Jul 2017 Status changed from completed to recruiting.